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Abstract
Background: High levels of dopamine (DA) were described in human ovary and recently evidence for
DA receptors in granulosa and luteal cells has been provided, as well. However, neither the full repertoire
of ovarian receptors for DA, nor their specific role, is established. Human granulosa cells (GCs) derived
from women undergoing in vitro fertilization (IVF) are an adequate model for endocrine cells of the follicle
and the corpus luteum and were therefore employed in an attempt to decipher their DA receptor
repertoire and functionality.
Methods: Cells were obtained from patients undergoing IVF and examined using cDNA-array, RT-PCR,
Western blotting and immunocytochemistry. In addition, calcium measurements (with FLUO-4) were
employed. Expression of two DA receptors was also examined by in-situ hybridization in rat ovary. Effects
of DA on cell viability and cell volume were studied by using an ATP assay and an electronic cell counter
system.
Results: We found members of the two DA receptor families (D1- and D2 -like) associated with different
signaling pathways in human GCs, namely D1 (as expected) and D5 (both are Gs coupled and linked to
cAMP increase) and D2, D4 (Gi/Gq coupled and linked to IP3/DAG). D3 was not found. The presence of
the trophic hormone hCG (10 IU/ml) in the culture medium for several days did not alter mRNA
(semiquantitative RT-PCR) or protein levels (immunocytochemistry/Western blotting) of D1,2,4,5 DA
receptors. Expression of prototype receptors for the two families, D1 and D2, was furthermore shown in
rat granulosa and luteal cells by in situ hybridization. Among the DA receptors found in human GCs, D2
expression was marked both at mRNA and protein levels and it was therefore further studied. Results of
additional RT-PCR and Western blots showed two splice variants (D2L, D2S). Irrespective of these
variants, D2 proved to be functional, as DA raised intracellular calcium levels. This calcium mobilizing effect
of DA was observed in the absence of extracellular calcium and was abolished by a D2 blocker (L-741,626).
DA treatment (48 h) of human GCs resulted in slightly, but significantly enlarged, viable cells.
Conclusion: A previous study showed D2 in human GCs, which are linked to cAMP, and the present
study reveals the full spectrum of DA receptors present in these endocrine cells, which also includes D2-
like receptors, linked to calcium. Ovarian DA can act thus via D1,2,4,5, which are co-expressed by endocrine
cells of the follicle and the corpus luteum and are linked to different signaling pathways. This suggests a
complex role of DA in the regulation of ovarian processes.
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Background
High levels of the catecholamine dopamine (DA) were
described in human ovary [1,2], raising questions about
its role in the female gonad. Several possibilities have so
far been suggested. It has been reported that monkey
(Macaca mulatta) oocytes are able to take up DA and use it
as precursor for the synthesis of noradrenaline (NE) [3],
with the help of dopamine-β-hydroxylase (DBH),
expressed by oocytes. NE may then be able to interact with
ovarian alpha- and beta-receptors present on granulosa
cells (GCs) of the follicle [2,4,5]. Furthermore, bovine
luteal cells are reported to perform synthesis of NE in a
similar way [6] and presumably this occurs also in intrao-
varian nerve fibers and neuron-like cells [7-9], which like-
wise express DBH. Thus, ovarian DA can be viewed as a
precursor for NE in oocytes, endocrine cells and nerve
cells and may have a plethora of functions (for example,
steroid production and induction of follicle-stimulating
hormone receptors) [9-11].
Nevertheless, recent publications have hinted to a yet dif-
ferent function. DA can, in general, act via its five different
receptor subtypes (D1-D5), which are organized in two
families (D1-like/D2-like) and one of them, D1, has been
described in human luteinizing GCs [12,13] and more
recently in endocrine cells of horse ovary [14]. In human
GCs, isolated from preovulatory follicles of women
undergoing in vitro fertilization (IVF) procedures, activa-
tion of D1 by selective agonists, as well as treatment with
DA itself, did not affect progesterone synthesis [12]. D1
activation was rather associated with cAMP elevations and
increased phosphorylation of DARPP-32 (DA and cAMP
regulated phospho-protein of MR 32,000), which is a
down-stream third messenger of DA, but also with other
signaling molecules in ovary and other tissues [12,13,15-
18].
Whether other receptors for DA are present in ovary and
on GCs and may thus provide a basis for its action, has as
yet not been thoroughly examined. However a recent
description of D2 in horse granulosa and luteal cells [14]
prompted us to examine whether this and other DA recep-
tors are also present in rat and human ovary. For func-
tional studies we focused on human GCs.
Methods
Human cells: GC preparation and culture
Human GCs were obtained from follicular aspirates of
women undergoing IVF, as described [12,13,19-21]. They
were separated by centrifugation at 560 × g for 3 min and
subsequent washing in serum-free DMEM/Ham's F-12
medium (1:1, Sigma, Deisenhofen, Germany). Washed
cells were resuspended in culture medium supplemented
with penicillin (100 U/ml), streptomycin (100 µg/ml),
and 10% fetal calf serum as previously described [20]. The
use of the cells for scientific experiments had been
approved by the ethic's committee of the University of
Munich (LMU), and written consent of the patients was
obtained. For Ca2+ imaging and immunocytochemistry
experiments, cells were cultured on glass cover slips, oth-
erwise in plastic dishes or well plates in a humidified
atmosphere with 5% CO2 at 37°C. Cells were used for the
experiments described either on day 3 or day 4 after isola-
tion. One group of cells was cultured with basal medium,
which for the other group was supplemented with hCG
(Sigma, 10 IU/ml; from the 1st day of culture).
cDNA arrays
Cells cultivated for 3 days were harvested and total RNA
was prepared as previously described [9,13,19,20] using
RNEasy kit (Qiagen, Hilden, Germany). A total of 5 ng
was used for the GEArray Q Series Human Neuroscience-
1 Ion Channel & Transporter Gene Array (SuperArray Bio-
science Corporation, Biomol, Hamburg Germany), as
described [20], following the instructions of the manufac-
turer. The array included D1, D2, D3, D5, but not D4, in
quatriplicate spots. Negative controls consisted of puc18
plasmid cDNA. Chemiluminescence signals were
recorded.
RT-PCR
Total RNA from several batches of cultured GCs (3 and 4
days after isolation) was prepared using RNEasy kit (Qia-
gen). As previously described [12,22], total RNA (200–
500 ng) was subjected to reverse transcription, using ran-
dom primers (pdN6) and Superscript-RT II (Life Technol-
ogies, Karlsruhe, Germany). Commercial human brain
cDNA (BD CLONTECH, Inc., Heidelberg, Germany) was
used in addition.
Informations about the oligonucleotid primers for DA
receptors used are summarized in Table 1. The primers for
cyclophilin were identical to the ones described in [22]. As
in human, two isoforms of the D2 are generated by alter-
native splicing of exon 6 of the pre-messenger RNA,
changing the length of the third cytoplasmic loop
involved in the coupling to G proteins [23,24]. In order to
be able to distinguish between these variants, we used a
semi-nested, second PCR amplification approach. To be
able to detect the long form, we employed a further anti-
sense oligonucleotide primer complementary to the
cDNA sequence of the 6th exon present only in the long
form (see Table 1: nested D2 long: 5'- ACT GGG AAA CTC
CCA TT-3'). We used the antisense primer (see Table 1:
nested D2 common: 5'-GAG CAT CTC CAT CTC CA-3')
complementary to a common region of both receptor
splice variants. With this approach a 261 bp product
would correspond to the D2L and a 173 bp product to the
D2S.Reproductive Biology and Endocrinology 2007, 5:40 http://www.rbej.com/content/5/1/40
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In order to be able to evaluate at least semiquantitatively
possible changes after treatment of the cultures with hCG,
or to take into account small loading differences, in all
samples cyclophilin was co-amplified, as described before
[22].
The PCR reaction products were separated on 2% agarose
gels and visualized with ethidium bromide. The identities
of all PCR products were verified by direct sequencing
using one of the specific primers [20].
Measurements of intracellular Ca2+ concentrations
Ca2+ measurements were performed on human GCs (day
3 or 4) cultured on glass cover slips, as described [21,25].
Two groups of cells were examined, namely cells kept
without or treated with hCG (10 IU/ml; since the 1st day
of culture). Briefly, the medium was replaced by fresh
serum-free DMEM/Ham's F-12 medium containing 5 µM
fluo-4 AM (Molecular Probes, Eugene, OR, USA) and cells
were loaded for 30 min at 37°C and 5% CO2. Finally, cells
were washed in extracellular solution (140 mM NaCl, 3
mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES and
10 mM glucose; pH 7.4) and were put into a recording
chamber mounted on a TCS SP2 confocal microscope
(Leica Microsystems, Bensheim, Germany). DA and car-
bachol (Sigma) were applied in 0.1 µM and 100 µM,
respectively. The D2  selective antagonist used was L-
741,626 (1 nM, Tocris Cookson Inc. Missouri, USA).
Changes in fluorescence intensity were monitored for 10
min by sampling every 2 s at excitation and emission
wavelengths of 488 nm and 520 ± 20 nm, respectively.
The Ca2+ free experiments were done with extracellular
solution without Ca2+ plus EGTA (2 mM).
Immunocytochemistry
The cellular distribution of D1,2,4,5 proteins in cultured
GCs was determined by immunocytochemistry using
commercially available polyclonal antisera (rabbit anti-
D1 receptor, R&D, Berkeley, CA, AS-3512G, 1:500; rabbit
anti-D2, BioTrend Chemikalien Gmbh, Köln, Germany,
AS-3526S, 1:500; rabbit anti-D4; Chemicon International
Inc., Temecula, CA, AB9422, 1:200; rabbit anti-D5, R&D,
Berkeley, CA, AS 3552G, 1:200). GCs were fixed on slides
(Zamboni's fixative) and used directly after rinsing in 10
mM PBS (pH 7.4). Incubation with the antiserum was car-
ried out overnight in a humidified chamber. A fluorescein
isothiocyanate-labeled secondary goat anti-rabbit antise-
rum was used. For control purposes, the first antiserum
was omitted, and incubations with normal rabbit serum
were carried out instead. Sections were examined with a
Zeiss Axiovert microscope (Zeiss, Oberkochen, Germany),
equipped with a fluorescein filter set.
Table 1: Informations about oligonucleotide primers used for PCR amplification: Sense, antisense and antisense nested primer 
sequences, as well as their positions in the published D1-D5 sequences are provided.
Human dopamine receptor D1 Sequence Genebank accession number/location of primer
NM_000794
sense 5'-CTG AAG ACT CTG TCG GTG A-3' (1756–1774)
antisense 5'-ACT CAC CGT CTC TAT GGC A-3' (2031-2013)
nested 5'TGT AGC ATC CTA AGA GGG T-3' (1990-1972)
Human dopamine receptor D2 NM_000795
sense 5'-TTC TAC GTG CCC TTC AT-3' (757–772)
antisense 5'-GGT CTG GAT CTC AAA GA-3' (1200-1184)
nested D2 common 5'-GAG CAT CTC CAT CTC CA-3' (1017-1000)
nested D2 long 5'- ACT GGG AAA CTC CCA TT-3' (959-943)
Human dopamine receptor D3 NM_000796
sense 5'-GGT ACT GGC CTT TGC TGT GTC C-3' 905–926
antisense 5'-ATC CTT TTC CGT CTC CTT TGT TTC-3' 1099-1076
nested 5'-CCA AAG GGC AGG TAG AAG GAC-3' 1036-1016
Human dopamine receptor D4 NM_000797
sense 5'-CCT TGC GGC TCC AAC TGT G-3' 913–931
antisense 5'-AGC GCC TGC GTG ATG TGC-3' 1112-1095
nested 5'-GAA GGC CCC GAC CAC CAC-3' 1065-1048
Human dopamine receptor D5 NM_000798
sense 5'-GGG CAG TTC GCT CTA TAC CAG-3' 88–108
antisense 5'-CAG GAA AAG GTC TGA CAC GG-3' 321-302
nested 5'-CAG AGA CAC GAT GAA GAC GTT-3' 300-280Reproductive Biology and Endocrinology 2007, 5:40 http://www.rbej.com/content/5/1/40
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Western blot analyses
Western blotting was performed as previously described
[12,13,18]. In brief, GCs cultured with or without hCG
(10 IU/ml for up to 4 days) were harvested, frozen,
thawed, homogenized in 62.5 mM Tris-HCl buffer (pH
6.8) containing 10% sucrose and 2% SDS, sonicated, and
heated (95°C for 5 min) in the presence of 10% mercap-
toethanol. Samples (15 µg/lane) were separated electro-
phoretically on 10% or 12.5% SDS-polyacrylamide gels
(SDS/PAGE). Proteins were transferred onto nitrocellu-
lose membranes and probed with D1 and D2 antisera, as
used for immunocytochemistry (1:1,000 dilution).
Immunoreactivity was detected using peroxidase-labeled
antisera (1:3,000, Dianova, Hamburg, Germany) and
enhanced chemiluminescence, as described [12,13,18]
(Amersham Buchler, Braunschweig, Germany). In some
cases, the blots were digitized, and integrated optical den-
sities of the bands were determined using an edited ver-
sion of the program NIH Image, as described previously
[12,13,18]. To be able to detect small differences in load-
ing, blots were also probed with mouse anti beta-actin
antibody (Sigma). Three independent experiments were
evaluated.
Cell volume and viability
To determine whether DA can affect cell viability or vol-
ume, cells were seeded in duplicate in 24-well tissue cul-
ture plates and stimulated for 48 h with or without DA
(10 µM). After that the cells were trypsinized and the aver-
age cell volume was examined using an electronic Coulter
counter (CASY-TT, Schärfe System, Reutlingen, Germany).
To determine viability of cells in culture the CellTiter-Glo®
Luminescent Cell Viability Assay (Promega) was used.
Cells were seeded in triplicate in 48-well tissue culture
plates and stimulated for 48 h with DA (10 µM). The kit
reagents were added directly to the cells in the well plate
and luminescence of luciferase reaction, as a marker of cell
viability, was measured with FLUOstar OPTIMA (BMG
LABTECH GmbH, Offenburg/Germany).
Rat tissues
Ovaries from four adult, cycling Sprague-Dawley rats
(Charles River, Sulzfeld Germany) [26] were quickly
removed and processed as described previously [26]. The
phases of the estrus cycles were not recorded. All methods
unless specified, were previously described in detail
[3,9,12,13,27,28].
In situ hybridization (ISH)
The ISH procedures were performed as described previ-
ously [26,28,29]. Briefly, cryostat sections of ovaries were
probed with a digoxigenin-uridine triphosphate labeled
cRNA antisense or for control purposes, with sense
probes. Templates for generation of riboprobes were par-
tial RT-PCR derived cDNAs: rat D2 (291 bp partial cDNA
subcloned in pGEM3Z; corresponding to position 1602–
1893; see [30], Genbank accession NM_012547) and rat
D1 (396 bp in pSP72, corresponding to 484–880; see [31],
Genbank accession M35077). These templates were a gift
from S. Ojeda to A. Mayerhofer. Riboprobes were tran-
scribed with T7 RNA polymerase (Promega) or with SP6
RNA polymerase (Promega). Experiments were per-
formed using sections of 4 individual rat ovaries.
Statistics
Data are expressed as mean + SEM unless indicated other-
wise in the text and graphs. Statistical significance of
changes was determined using ANOVA and Newman-
Keuls's post test (Ca2+ measurements) and by paired Stu-
dent's t-test (comparison of cell volumes and ATP assay),
performed with GraphPad Prism version 4.0a for Macin-
tosh (GraphPad Software, San Diego California USA). Sta-
tistical significance was accepted for p < 0.05.
Results
1. Evidence for D1,2,4,5 expression in human GCs
We tested which DA receptors are present in human GCs,
i.e. a cell type derived from large preovulatory follicles,
which are in the process of differentiation into luteal cells
(Fig. 1, 2, 3).
RT-PCR experiments performed with mRNA obtained
from GCs on the 3rd or 4th day of culture yielded cDNAs
of expected sizes (Fig. 1), which upon sequencing proved
to be identical to the known human D1,2,4,5 sequences.
Gene expression of DA receptors D1,2,4,5 in human GCs Figure 1
Gene expression of DA receptors D1,2,4,5 in human 
GCs. Ethidium bromide-stained agarose gel showing RT-
PCR products, which correspond to expected size of D1,2,4,5 
cDNAs in GCs (day 3 and day 4 of culture, with and without 
hCG stimulation). After sequencing they proved to be identi-
cal to the human D1,2,4,5. Results of PCR amplification were 
not visibly different between cells treated with or without 
hCG, as judged from similar bands and similar levels of cyclo-
philin, which was also amplified. Control (CO) was without 
input mRNA in RT-PCR reactions. The gel shows results 
obtained from one of four experiments that yielded compa-
rable results.Reproductive Biology and Endocrinology 2007, 5:40 http://www.rbej.com/content/5/1/40
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Experiments using specific primers for D3 did not yield
results. The presence of hCG in the medium did not alter
levels of DA receptor D1,2,4,5 mRNAs, as judged from
semiquantitative RT-PCR experiments when cyclophilin
was used for normalization (Fig. 1).
Results of gene array experiments provided evidence for
the presence of D1,2,5 (D4 was not represented on the array
membrane; D3 was found to be not expressed; data not
shown except for D2, see Fig. 3A).
By immunocytochemistry D1,2,4,5 receptors proteins were
also demonstrated in virtually all GCs using specific
D1,2,4,5 receptor antisera. D1,2,4,5 immunoreactivities were
associated mainly with the cytoplasm of all GCs, and all
controls performed were negative (Fig. 2). D2 immunore-
activity appeared to be strongest.
D2 receptor splice variant
For the human D2 we found evidence of the long splice
variant, D2L, and also the short form was obtained using
semi-nested second PCR steps, albeit the presence of this
splice variant was inconsistent and appeared not to be
associated with treatment or time in culture (Fig. 3B).
Both splice variants were found also at the protein level by
Western blot (Fig. 3C).
2. Evidence for D1,2 receptor gene expression in rat ovary
In situ hybridization revealed that D1 and D2 mRNAs are
present in rat ovarian endocrine cells. Signals were detect-
able only when antisense cRNA was used, but not in sense
cRNA controls. Signals were associated with GCs of folli-
cles, but were stronger in theca and interstitial cells and
the corpus luteum (Fig. 4).
3. Elucidation of D2 receptor functionality in human GCs
Changes of intracellular Ca2+ levels in human GCs
The functionality of D2 (both S and L splice forms) is
linked to intracellular Ca2+ levels, which we thus moni-
tored in human GCs. The addition of DA (0.1 µM) rapidly
increased intracellular Ca2+ levels (Fig. 5A). The number
of the cells responsive to DA was lower than in the posi-
tive control, used for methodological comparison,
namely the acetylcholine analogue carbachol [21].
Furthermore, the specificity of the DA action was shown
by using the D2 blocker L-741,626 (1 nM), which pre-
vented the Ca2+ increases (Fig. 5B; n = 7 experiments with
60–90 cells each). The response was not depending on the
presence of extracellular Ca2+ in the medium, indicating
D1,2,4,5 protein detection in human GCs Figure 2
D1,2,4,5 protein detection in human GCs. Immunofluo-
rescence localization of the D1,2,4,5 proteins in cultured GCs 
(day 3 after isolation). Control (Co), omission of antisera. 
Bar is equivalent to 40 µm; antisera dilutions 1:500. D2 in human GCs Figure 3
D2 in human GCs. A) Result of cDNA array, showing evi-
dence for expression of D2. B) Ethidium bromide-stained 
agarose gel showing RT-PCR products which identify D2L 
(261 bp) and D2S (173 bp). Note that D2L is consistently 
expressed, while D2S expression is not depending on age or 
treatment with hCG (day 4 of culture, n = 4/each). C) West-
ern blot analysis of D2 in cultured human GCs. Cells were 
treated without or with hCG for 4 days and 15 µg of total 
protein was analyzed. Note that the treatment has no effect 
on the overall levels of D2 protein, which can be readily 
detected as a double band of about 48 and 51 kDa, repre-
senting D2S and D2L, respectively. Subsequent detection of 
beta actin in the same blots was also performed to normalize 
the density of the bands. Data shown are from one of three 
independent experiments yielding similar results.Reproductive Biology and Endocrinology 2007, 5:40 http://www.rbej.com/content/5/1/40
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release from intracellular sites (data not shown, n = 4
experiments with 20–50 cells each).
Interestingly, the numbers of cells responsive to DA by
intracellular Ca2+ elevations were significantly (p < 0.05)
higher when GCs were cultured in the presence of hCG, as
compared to untreated cultures. The percentage of
responding GCs to DA without hCG stimulation was
10.2% and 3.7% on the 3rd and on the 4th day of culture,
respectively. After hCG exposure the percent of reacting
cells was 24% and 21% on day 3 and 4, respectively, indi-
cating a role of hCG in promoting D2 functionality (Fig.
5C).
4. Effects of DA on cell viability and volume of human GCs
Human GCs exposed to DA (10 µM) for 48 h significantly
increased the cell volume (Fig. 6A; control: 8085 ± 906
femto liters (fl); DA 10 µM: 10389 ± 1053 fl; n = 4, p <
0.05; determined with CASY-TT). Furthermore, the luci-
ferase ATP assay showed a significant increased signal
when the GCs were stimulated for 48 h with DA (Fig. 6B;
control: 100%; DA 10 µM: 108.7 ± 0.7 %; n = 3, p < 0.05).
In this assay the signal is proportional to the amount of
ATP present, which correlates with the number of viable
cells and/or their size. Concomitant increases in cellular
volume and in ATP levels imply that the average sizes of
viable cells is increased after treatment with DA. Co-
expression of multiple DA receptors on each cell and lack
of specific tools to distinguish between the different DA
receptor members in primary cells, kept us from further
investigations.
Discussion
Catecholamines, especially NE, have long been impli-
cated in the control of ovarian function [1-9], but whether
the catecholamine DA has a specific function within the
ovary is not known. A prerequisite for such an action is the
presence of functional receptors in the ovary. Our results
show that most of the DA receptors are present in human
GCs and that two members of each DA receptor family
linked to different signaling pathways are co-expressed.
Our results also show expression of two prototype DA
receptor family members (D1/D2) in rat ovarian endo-
crine cells. This resembles the previously shown expres-
sion in horse ovary and extend our studies in human and
monkey ovary [14].
For our studies we employed cultured human GCs, which
stem from the preovulatory follicle and are undergoing
luteinization. These like monkey granulosa and luteal
cells, express D1 [12,13] and as we found also D5. A previ-
ous study has shown that this receptor is linked to cAMP
and DARPP-32 phosphorylation [12,13]. D1  and D5
together are known also as the D1-like subfamily of DA
receptors, which is linked to Gs and to a similar signaling
pathway. It is possible that due to co-expression of D1/D5,
which we have now observed, parts of the effects ascribed
previously to D1 are actually due to (co)-activation of both
receptors. The agonists/antagonist available in the con-
centrations we can use in our model, does not allow to
distinguish between these subtypes or draw further con-
clusions [32-34].
The other D2-like subfamily of DA receptors consists of
D2,3,4, of which two were found in human GCs, as well. D2
appeared to be strongly expressed, as judged from our
results using a gene array, as well as immunocytochemis-
try and Western blotting. This subtype is also expressed in
horse ovarian endocrine cells [14] and in rat follicles and
corpus luteum (this study). We therefore chose to investi-
gate this receptor subtype further.
That D2 mRNA can be alternatively spliced became evi-
dent in our study, as well. Evidence for constant expres-
sion of the long form splice variant (D2L) was obtained,
while the short form (D2S) was found in an inconsistent
manner and appeared not to be associated with time in
culture. The antiserum used for both immunocytochemis-
try and Western blot detects both forms and either exper-
iment indicated ubiquitous presence and high levels in all
In situ hybridization – rat ovary Figure 4
In situ hybridization – rat ovary. Non-radioactive in situ 
hybridization experiments of rat ovarian slices with D1 or D2 
antisense cRNA show strongest signals in theca and intersti-
tial cells (TC/ISC) and the corpus luteum (CL), while follicu-
lar GCs (asterisk) reveal only a moderate signal. All signals 
are absent from a D1 and D2 receptor sense control. Bar: 
approximately 100 µm.Reproductive Biology and Endocrinology 2007, 5:40 http://www.rbej.com/content/5/1/40
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cultured GCs. Effects of hCG on mRNA and protein levels
of this subtype or on possibly splice variants were also not
obvious with the experimental approach chosen, and no
changes were observed with regard to the expression of
the other DA receptors in GCs, as well.
It is well established that action of DA on either splice var-
iant of the D2 is linked to a phosphatidylinositol-linked
mobilization of intracellular Ca2+ [35]. Although all cells
appeared to express the receptor protein, we found when
we measured the Ca2+ response of individual cells to DA
that only a percentage of the cultured cells showed indeed
the expected changes. Furthermore, although we did not
detect changes in overall levels of D2 in the presence of
hCG in the culture medium, the percentage of responding
GCs was significantly higher under these circumstances as
compared to untreated cultures. The dependency on cul-
ture time or the presence of hCG indicate a relationship of
the cellular differentiation state to D2 function and a role
of the trophic hormone hCG/LH in promoting D2 func-
tionality. Detailed insights e.g. at what level this may
occur, are currently not possible and it remains, likewise,
Measurements of intracellular Ca2+ concentrations in human GCs Figure 5
Measurements of intracellular Ca2+ concentrations in human GCs. A) Line plot graphic showing the time-course of 
intracellular Ca2+ changes for three representative cells sequentially treated with buffer (at t = 0), 0.1 µM DA, and 100 µM car-
bachol. Color images of fluo-4 AM loaded GCs of identical viewing areas are also provided. Color changes from red/yellow to 
yellow/blue represent increased intracellular Ca2+ levels. B) Line plot graphic showing the time-course of intracellular Ca2+ 
changes for three representative cells sequentially treated with buffer (t = 0), 1 nM L-741,626, 0.1 µM DA, and 100 µM carba-
chol, as a positive control. Data are expressed as relative fluorescence intensities corresponding to a pseudo color scale from 
red/yellow to yellow/blue. Experiments were repeated seven times with a total of 60 to 90 cells each examined in detail. C) 
Percentage of GCs responding to DA with increased intracellular Ca2+ levels. The graphic represents the percentage of GCs 
(day 3 or 4 of culture) responding to DA (0.1 µM) with an increase in the intracellular Ca2+ levels. GCs were either untreated 
or stimulated with hCG (10 IU/ml) since the 1st day of culture. Experiments were repeated seven times with a total of 60 to 90 
cells each examined in detail. Data represent means + SEM (ANOVA/post-test *p < 0.05).Reproductive Biology and Endocrinology 2007, 5:40 http://www.rbej.com/content/5/1/40
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to be investigated whether possible transactivation of the
D2, e.g. by EGF receptor [36] or other as yet unknown
interactions may be involved.
In human the two splice variants, D2S and D2L, exhibit dif-
ferences in the length of the third cytoplasmic loop
involved in the coupling to G proteins [23,24] and intrac-
ellular signaling [37,38] other than phosphatidylinositol-
linked mobilization of intracellular Ca2+. For example in
neurons, D2L which is constantly present in human GCs,
is in general also associated with inhibition of cAMP syn-
thesis, stimulation of the MAP kinase pathway, activation
of G protein coupled inwardly rectifying potassium chan-
nels (GIRKs), inhibition of Ca2+ channels, potentiation of
arachidonic acid release and increased Na+/K+-ATPase
activity [39,40]. In the present report on this subject we
were not able to address the full plethora of possible
actions, but focused on effects of DA to mobilize Ca2+,
which, by use of a specific D2 antagonist, were clearly
shown. The Ca2+ mobilizing effect of DA was not depend-
ent on the presence of extracellular Ca2+, i.e. it did most
likely not involve opening of Ca2+ channels in the plasma
membrane.
To summarize, human GCs possess four of the five known
DA receptors, one of which exists in two possible splice
variants and co-expression of these receptors is likely. Pos-
sible interactions of these DA receptors for example at the
intracellular level (including DARPP-32) are to be
assumed. Unfortunately the pharmacological tools avail-
able for the study of DA receptors in primary human GCs
are limited [32-34], and antagonists/agonists interact
often in a concentration-dependent manner with several
receptors. Other approaches including siRNA are not
readily possible for these primary cells. Clearly, the study
of such interactions would be of great interest, for exam-
ple with regard to DARPP-32, previously detected in
human GCs and ovarian endocrine cells [12,13,18] or
recently also in other endocrine tissue [41].
Therefore, a complete answer to the naive question about
a specific role of DA in the ovary, which we posed, can not
be given and may turn out to be much more complex than
anticipated. Yet, a partial answer is provided by the results
of the present study. By showing that four of the five
known DA receptors are present in endocrine ovarian
cells, they clearly indicate that DA is more than a precur-
sor of NE (see Introduction). Ovarian endocrine cells are
thus newly identified targets of ovarian DA and we
assume based on our current results complex interactions
between different DA receptor signaling cascades. Our
study only provides first hints to an outcome of such
actions, which implies a "trophic" role of DA for these
cells. We found that treatment of cultured cells for up to
48 h with DA increased their size and viability, suggesting
that DA may serve as a "differentiation factor". In brain,
trophic actions of neurotransmitter are established
[42,43]. Insights into actions of yet another prototype
neurotransmitter present in ovary, namely acetylcholine,
which stimulates GCs proliferation and differentiation,
supports the notions that neurotransmitters may act as
local growth factors outside the brain [44,45].
A role for ovarian DA is likely not restricted to GCs or
endocrine cells, as other ovarian cells (e.g. oocytes, [46] or
others) may have DA receptors or DA transporters, as well.
It remains also to be investigated, whether ovarian micro-
vasculature cells as reported in other tissues are affected by
DA, which could be a profound modulator of VEGF
actions and angiogenesis [46].
The presence of high ovarian DA levels on one side [1,47]
and of functional DA receptors on ovarian endocrine cells
Effect of DA on mean cellular volume and viability Figure 6
Effect of DA on mean cellular volume and viability. A) 
DA (10 µM) significantly (p < 0.05) increased the cellular vol-
umes of GCs (means + SEM of 4 experiments; 48 h). B) The 
treatment of human GCs with DA (10 µM; 48 h) resulted in 
significantly increased ATP levels (p < 0.05; means + SEM of 3 
experiments).Reproductive Biology and Endocrinology 2007, 5:40 http://www.rbej.com/content/5/1/40
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linked to different second messenger pathways, on the
other side, imply as yet unknown ovarian signaling sys-
tems and specific roles of DA also in the human ovary.
Furthermore, existence of the DA transporter and DBH in
oocytes [3] or luteal cells [3], indicate actions of DA as a
precursor for NE, within the ovary.
Taken together, these results may be of as yet unforeseea-
ble relevance to human ovarian function. This assump-
tion is based for example on the interaction of many drugs
[37] with components of the DA and the NE system,
including haloperidol, cocaine and others, which may be
able to affect the ovary directly. It also remains to be stud-
ied, whether like in brain, DA and steroid hormone sign-
aling may converge, a possibility shown for DA and
progesterone [48]. Finally, at least in animal studies, cate-
cholamines (mainly NE) have been implicated in poly-
cystic ovarian syndrome (PCOS; see [47]). Whether NE
and specifically the catecholamine DA and ovarian DA
receptors are involved in human PCOS, a common cause
of infertility in women, remains to be studied. Our pilot
studies indicate that in GCs from PCOS patients DA recep-
tors are expressed (unpublished).
Conclusion
The present study shows that DA receptors are expressed
by rat ovarian endocrine cells. Human GCs possess four of
the five known DA receptors, one of which exists in two
possible splice variants, and co-expression of these recep-
tors is likely. Our results provide a basis for future studies
addressing the role of these receptors for the ovary in
health and disease.
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